Table 3.
RBP1 methylation by reduced representation bisulfite sequencing (RRBS), methylation-sensitive restriction enzyme (MSRE), and The Cancer Genome Atlas (TCGA) analysis*
| IDH1 WT | IDH1 MUT | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Assay | No. of patients | No. of patients | Mean methylation (SD) | No. of patients | Mean methylation (SD) | Possible range | Actual range | P † | P ‡ |
| RRBS | 10 | 5 | 0.05 (0.02) | 5 | 0.68 (0.06) | 0–1.0 | 0.01–0.81 | <.001 | .008 |
| MSRE | 31 | 15 | 4.05 (0.57) | 16 | 7.82 (0.49) | −9.19–21.75 | 1.68–10.95 | <.001 | <.001 |
| TCGA | 147 | 124 | 0.14 (0.01) | 23 | 0.69 (0.08) | 0–1.0 | 0–0.98 | <.001 | <.001 |
* For RRBS and TCGA, the mean methylation represents the percentage of methylation in the region of interest. For MSRE, mean methylation represents standard deviations above known baseline (unmethylated) signal. IDH = isocitrate dehydrogenase; MUT = mutant; RBP1 = retinol binding protein 1; WT = wild type.
† Two-sided P was calculated by Student t test.
‡ Two-sided P was calculated by Wilcoxon test.